Partners of patients with melanoma find new cancers with skin exam training

Google+ Pinterest LinkedIn Tumblr +

Senior CoupleSkin-check partners of patients with melanoma effectively performed skin self-examinations and identified new melanomas as part of an effort to increase early detection of the skin cancer that can be fatal, according to the results of a clinical trial published online by JAMA Dermatology.

Patients with melanoma are at increased risk of developing a second primary melanoma. Patients with melanoma and their partners can help to manage early detection of new or recurrent melanoma with skin self-examination (SSE).

June K. Robinson, M.D., of the Northwestern University Feinberg School of Medicine, Chicago, and coauthors conducted a randomised clinical trial with 24 months of follow-up with patients with stage 0 to IIB melanoma and their skin-check partners.

The study enrolled 494 participants who were assigned to either usual care (n=99) or to the skill-based intervention for SSE, which was delivered either in-person in the office (n=165), in a workbook (n= 159) or on a tablet (n=71). Skills to recognise change in the border, color and diameter of moles were reinforced in four-month intervals during skin examinations by a dermatologist.

skin check melanoma mole_oncology news australiaOf the 494 patients, 66 developed new melanomas. Patient-partner pairs in intervention (n=395) identified 43 melanomas. In comparison, none of the patient-partner pairs in the comparison control group identified melanoma, according to the results.

Study limitations include relying on self-reported survey responses.

“Future research will determine if a skills training program delivered via the web without reinforcement by the dermatologist will yield reliable sustained performance of SSE by those at risk to develop another melanoma,” the study concludes.
[hr] PaperJAMA Dermatology. Published online June 29, 2016. DOI: 10.1001/jamadermatol.2016.1985
SourceThe JAMA Network Journals

Share.

About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Comments are closed.